Table 1.

Efficacy of trastuzumab on primary and metastatic esophageal cancer

A. Control group
Mouse #PT weight (g)PTPT HER-2+MetastasisMetastasis HER-2+LN metastasisLN metastasis HER-2+
11.7++++++
20.7++
32.4++++++
45.4++++++
51.8++++++
61.9++++++
72.6++
Overall2.36100%100%71%100%71%100%
B. Herceptin-treated group
Mouse #PT weight (g)PTPT HER-2+MetastasisMetastasis HER-2+LN metastasisLN metastasis HER-2+
10.6++++
20.7++
31.7++
41.6++++++
51.5++
60.5++++++
70.3++
81.8++++++
Overall1.09100%100%50%100%37.5%100%

NOTE: In the control group (A) 100% of mice showed primary tumor (PT) growth and the overall metastatic rate was 71%. In all mice with metastases, lymph node (LN) metastases were found. In the trastuzumab-treated group (B), although 100% of the mice showed primary tumor growth, the tumor weight was significantly lower (P = 0.044). The overall metastatic frequency was reduced to 50% and lymph node metastases were reduced to 37.5% in the treated as opposed to 71% in the untreated group.